Back To Search Results

Ecthyma Gangrenosum

Editor: Jonathan S. Crane Updated: 6/28/2023 3:41:16 PM


Ecthyma gangrenosum (EG) is a cutaneous infection that most commonly occurs in immunocompromised individuals with fulminant bacteremia. EG was first described in 1897 by Canadian pathologist Dr. Lewellys Barker as a manifestation of Pseudomonas aeruginosa.[1] Although P. aeruginosa remains the most frequent organism identified in EG, other causative pathogens have since been described. Lesions appear as gangrenous ulcers with erythematous borders. EG predominantly affects the axillary and anogenital areas, but the arms, legs, trunk, and face are also sometimes involved. Perivascular invasion and resultant ischemic necrosis of the associated skin result in the classic macroscopic appearance. Prompt recognition and empiric therapy with broad-spectrum antipseudomonal agents are of critical importance. Once microbiology results identify the causative pathogen and sensitivities are available, antimicrobial coverage should be narrowed.[2] EG denotes a poor prognosis, particularly in immunocompromised individuals with neutropenia.


Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care


P. aeruginosa is the most frequent organism identified in ecthyma gangrenosum, with one study identifying P. aeruginosa in 74% of cases.[1] P. aeruginosa is a non-lactose fermenting gram-negative aerobic, rod-shaped bacteria. The organism is found in moist environments, is often identified in tap water samples, and can contaminate hospital equipment leading to nosocomial infections.[3][4] Other causes of EG include methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus pyogenesCitrobacter freundii, Escherichia coliAeromonas hydrophila, Klebsiella pneumoniae, Serratia marcescens, Xanthomonas maltophilia, Morganella morganii, Corynebacterium diphtheriae, Neisseria gonorrhea, Yersinia pestis, fungi like the Candida species), and viruses like herpes simplex virus.[1][5][6][7]


Ecthyma gangrenosum affects all age groups and genders. Immunocompromised individuals are particularly susceptible to developing this condition, with up to 62% to 75% of affected individuals having an underlying immunodeficiency.[1][8] EG is also known to occur in otherwise healthy immunocompetent individuals.[9] Common predisposing conditions include neutropenia, leukemia, multiple myeloma, diabetes mellitus, malnutrition, and extensive burn wounds.[1][5][7][10][11]


Ecthyma gangrenosum is separated into bacteremic and non-bacteremic forms.[7] The bacteremic form of EG is more common than the non-bacteremic form.[1] With bacteremia, the causative organism is spread hematogenously to the capillaries and invades the media and adventitia of arteries and veins. Perivascular invasion ultimately leads to ischemic necrosis of the surrounding skin.[12] In the non-bacteremic form, the lesions develop at the location of direct inoculation into the epidermis. Virulence toxins and enzymes produced by P. aeruginosa, such as exotoxin A, elastase, and phospholipase C, cause skin and vascular destruction.[8] Multi-drug resistance of P. aeruginosa has increased substantially in recent years, making treatment more challenging. Resistance mechanisms include decreased permeability (biofilm formation), antibiotic efflux pumps, antibiotic inactivating mechanisms, and antibiotic target site mutations.[12][13]


Excisional biopsy or punch biopsy with Gram stain, culture, and histopathologic examination can be performed in equivocal cases. In cases of pseudomonal EG, Gram stain shows many gram-negative, rod-shaped bacteria.[14] Wound cultures are frequently positive for P. aeruginosa but may reveal a different causative organism. Microscopic examination reveals an ulcerated zone of necrotic epidermis and dermis with neutrophilic predominance.[14][15] The epidermis adjacent to the necrotic region reveals reactive hyperkeratosis. The underlying subcutaneous tissue may also be involved.[8]

History and Physical

When acquiring a history on presentation, it is important to note the temporal evolution of the lesions, the location of the lesions, any underlying immunosuppressive condition, and other associated symptoms such as cough, fever, or dysuria. In individuals with the bacteremic form of EG, the source of infection is important to ascertain. For example, productive cough or dysuria may reveal a respiratory or urinary source, respectively. In the non-bacteremic form, it is important to note any trauma that may have introduced the infection via direct inoculation.

The lesions of ecthyma gangrenosum begin as painless, round erythematous macules and patches that develop into central pustules with surrounding erythema. A hemorrhagic vesicle appears at the center of the lesion and evolves into a gangrenous ulcer with a black eschar.[1][8] Early lesions may progress to necrotic ulcers in as little as 12 hours.[8] The lesions can be localized and solitary, or widespread.[1] 

EG can appear anywhere in the body but most commonly affects the anogenital and axillary areas. The gluteal/perineal area is most common (57%), followed by the extremities (30%), the trunk (6%), and the face (6%).[8] Rare cases of periorbital involvement have also been reported.[8] The entire body should be examined for lesions, and any fluctuance or large areas of necrosis should be noted.


Initial evaluation includes blood cultures, wound cultures, urinalysis, chest radiograph, complete blood count, comprehensive metabolic panel, C-reactive protein, and HIV testing. Procalcitonin and lactate levels are important in those with EG in the setting of sepsis. Evaluation of the lesions with a Wood's lamp may expedite the diagnosis, as P. aeruginosa will appear with green fluorescence.[8][16] Excisional or punch biopsy can be performed in equivocal cases.

Treatment / Management

In individuals with suspected ecthyma gangrenosum, prompt treatment with broad-spectrum antibiotics should be initiated after obtaining blood and wound cultures. 

Initial empiric therapy includes antipseudomonal beta-lactams (piperacillin/tazobactam), cephalosporins (cefepime), fluoroquinolones (levofloxacin), and carbapenems (imipenem). Combination therapy is recommended in high-risk individuals, such as those with neutropenia and septic shock.[12] Once the causative organism and antimicrobial susceptibilities are identified, antimicrobial coverage should be narrowed.[2] In rare cases with a fungal or viral etiology, anti-fungal and anti-viral agents should be started.

Surgical excision of necrotic lesions or abscesses is often necessary. Incision and drainage of abscesses are important for source control of the infection. For necrotic skin lesions, aggressive debridement and grafting may be necessary for lesions larger than 10 cm.[8]

Treatment in the hospital intensive care setting is appropriate for patients with sepsis or neutropenia due to the high case fatality rate. For those with non-bacteremic EG, treatment in the outpatient setting may be appropriate. In this setting, oral antipseudomonal agents, such as ciprofloxacin, can be considered.

Differential Diagnosis

A thorough history, physical, and basic laboratory studies help differentiate between EG and other causes of skin necrosis. Neutropenia and malignancy in a patient with typical skin lesions should raise suspicion for EG. Other conditions with similar macroscopic features include autoimmune vasculitides, vasopressor-induced necrosis, calciphylaxis, warfarin-induced necrosis, and disseminated intravascular coagulation (DIC), pyoderma gangrenosum, necrolytic migratory erythema, and livedoid vasculopathy.[1][17][18]

In individuals with underlying malignancy and pancytopenia, fibrinogen levels and fibrin split products (d-dimer) can help differentiate DIC from EG. In individuals in the intensive care unit on vasopressors, the distribution of lesions can help differentiate between vasopressor-induced necrosis and EG. Vasopressor-induced necrosis affects the distal extremities, while EG affects the anogenital and axillary areas.[19] Tissue samples are critical when the diagnosis is not clear based on less invasive methods.[20]


The development of EG lesions in individuals with sepsis is associated with a poor prognosis and is fatal in 20% to 77% of patients.[15][21] In individuals with non-bacteremic EG, the mortality rate is significantly lower at 8%.[15] The underlying immunosuppressive state (e.g., malignancy, renal failure, or other) is often the main determinant of clinical outcome.[22] The presence of neutropenia at the time of diagnosis is the most important prognostic factor of mortality.[21]


EG is a life-threatening infection often complicated by septic shock. Prompt clinician recognition and appropriate antimicrobial therapy are necessary to achieve optimal outcomes.

Deterrence and Patient Education

Patients need to understand that if they are immunocompromised, that underlying condition requires optimal management. These patients are typically managed in the hospital setting.

Pearls and Other Issues

  • P. aeruginosa is the most common causative organism of ecthyma gangrenosum.
  • Lesions appear as gangrenous ulcers with erythematous borders located predominantly in the axillary and anogenital areas.
  • Nearly all individuals with typical skin lesions are immunocompromised, with malignancy being the most common underlying disease state.
  • Neutropenia at the time of diagnosis is the most important prognostic factor.
  • Prompt treatment with intravenous antipseudomonal agents is indicated.
  • Incision and drainage may be performed for abscesses.

Enhancing Healthcare Team Outcomes

Management of ecthyma gangrenosum requires an interprofessional team approach, including providers from infectious disease, surgery, dermatology, hematology, and critical care. The providers involved in treatment depend on the overall clinical picture and whether they are being treated in the intensive care unit.

A dermatologist can help in the initial diagnostic workup to determine the cause (Wood's lamp evaluation, punch biopsy) and extent of the lesions. Infectious disease specialists are helpful to determine the selection and length of antibiotic therapy. Surgeons may be needed for incision and drainage of multiple abscesses, surgical debridement of necrotic lesions, or grafting of large-area defects. In patients with neutropenia, granulocyte colony-stimulating factor (G-CSF) may be given at the discretion of a hematologist.

For individuals with fulminant sepsis, management in the critical care setting by an intensivist is appropriate due to the high fatality rate of bacteremic EG. Individuals with sepsis are extremely tenuous, and careful monitoring from the nursing staff with frequent vital sign measurements is critical and reporting to the team untoward changes. Prompt administration of effective antimicrobial therapy is known to improve survival in sepsis.[23] [Level 1] Ideally, an infectious disease specialist pharmacist should assist with antibiotic selection and assist the team with dose management. In addition to helping to target the causative organism. Early goal-directed therapy focusing on blood pressure and oxygen saturation has also been shown to improve outcomes and reduce mortality in sepsis.[24] [Level 1]



Vaiman M,Lazarovitch T,Heller L,Lotan G, Ecthyma gangrenosum and ecthyma-like lesions: review article. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2015 Apr     [PubMed PMID: 25407372]


Leekha S,Terrell CL,Edson RS, General principles of antimicrobial therapy. Mayo Clinic proceedings. 2011 Feb     [PubMed PMID: 21282489]


Mulcahy LR,Isabella VM,Lewis K, Pseudomonas aeruginosa biofilms in disease. Microbial ecology. 2014 Jul     [PubMed PMID: 24096885]

Level 3 (low-level) evidence


Georgieva V,Dimitrova Y, Study of the Microbiological Quality of Bulgarian Bottled Water in Terms of Its Contamination with Pseudomonas Aeruginosa. Central European journal of public health. 2016 Dec     [PubMed PMID: 28095290]

Level 2 (mid-level) evidence


Hawkley T,Chang D,Pollard W,Ferraro D, Ecthyma gangrenosum caused by {i}Citrobacter freundii{/i}. BMJ case reports. 2017 Jul 27     [PubMed PMID: 28751433]

Level 3 (low-level) evidence


R G S,Muralidhar V, Non-pseudomonal ecthyma gangrenosum caused by methicillin-resistant S{i}taphylococcus aureus{/i} (MRSA) in a chronic alcoholic patient. BMJ case reports. 2017 Aug 3     [PubMed PMID: 28775089]

Level 3 (low-level) evidence


Reich HL,Williams Fadeyi D,Naik NS,Honig PJ,Yan AC, Nonpseudomonal ecthyma gangrenosum. Journal of the American Academy of Dermatology. 2004 May     [PubMed PMID: 15097944]

Level 3 (low-level) evidence


Vaiman M,Lasarovitch T,Heller L,Lotan G, Ecthyma gangrenosum versus ecthyma-like lesions: should we separate these conditions? Acta dermatovenerologica Alpina, Pannonica, et Adriatica. 2015     [PubMed PMID: 26697730]


Biscaye S,Demonchy D,Afanetti M,Dupont A,Haas H,Tran A, Ecthyma gangrenosum, a skin manifestation of Pseudomonas aeruginosa sepsis in a previously healthy child: A case report. Medicine. 2017 Jan     [PubMed PMID: 28079790]

Level 3 (low-level) evidence


Korte AKM,Vos JM, Ecthyma Gangrenosum. The New England journal of medicine. 2017 Dec 7     [PubMed PMID: 29211664]


Bettens S,Delaere B,Glupczynski Y,Schoevaerdts D,Swine C, Ecthyma gangrenosum in a non-neutropaenic, elderly patient: case report and review of the literature. Acta clinica Belgica. 2008 Nov-Dec     [PubMed PMID: 19170356]

Level 3 (low-level) evidence


Bassetti M,Vena A,Croxatto A,Righi E,Guery B, How to manage {i}Pseudomonas aeruginosa{/i} infections. Drugs in context. 2018     [PubMed PMID: 29872449]


Lee K,Yoon SS, {i}Pseudomonas aeruginosa{/i} Biofilm, a Programmed Bacterial Life for Fitness. Journal of microbiology and biotechnology. 2017 Jun 28     [PubMed PMID: 28301918]


Frey JD,Latkowski JA,Louie E,Chiu ES, Diagnosis and management of ecthyma gangrenosum in chronic renal failure patient. Archives of plastic surgery. 2014 May     [PubMed PMID: 24883286]


Sarkar S,Patra AK,Mondal M, Ecthyma gangrenosum in the periorbital region in a previously healthy immunocompetent woman without bacteremia. Indian dermatology online journal. 2016 Jan-Feb     [PubMed PMID: 26955586]


Ponka D,Baddar F, Wood lamp examination. Canadian family physician Medecin de famille canadien. 2012 Sep     [PubMed PMID: 22972730]


Ozel Coskun BD,Karaman A,Gorkem H,Buğday I,Poyrazoğlu OK,Senel F, Terlipressin-induced ischemic skin necrosis: a rare association. The American journal of case reports. 2014 Oct 31     [PubMed PMID: 25360696]

Level 3 (low-level) evidence


Hafner J, Calciphylaxis and Martorell Hypertensive Ischemic Leg Ulcer: Same Pattern - One Pathophysiology. Dermatology (Basel, Switzerland). 2016     [PubMed PMID: 27622522]


Daroca-Pérez R,Carrascosa MF, Digital necrosis: a potential risk of high-dose norepinephrine. Therapeutic advances in drug safety. 2017 Aug     [PubMed PMID: 28781738]

Level 3 (low-level) evidence


Fernandes SR,Baldaia C,Gonçalves AR, Genital Ischemia in a Patient Under Terlipressin Therapy. GE Portuguese journal of gastroenterology. 2016 Jul-Aug     [PubMed PMID: 28868464]


Martínez-Longoria CA,Rosales-Solis GM,Ocampo-Garza J,Guerrero-González GA,Ocampo-Candiani J, Ecthyma gangrenosum: a report of eight cases. Anais brasileiros de dermatologia. 2017 Sep-Oct     [PubMed PMID: 29166510]

Level 3 (low-level) evidence


Grisaru-Soen G,Lerner-Geva L,Keller N,Berger H,Passwell JH,Barzilai A, Pseudomonas aeruginosa bacteremia in children: analysis of trends in prevalence, antibiotic resistance and prognostic factors. The Pediatric infectious disease journal. 2000 Oct     [PubMed PMID: 11055596]

Level 2 (mid-level) evidence


Kumar A,Roberts D,Wood KE,Light B,Parrillo JE,Sharma S,Suppes R,Feinstein D,Zanotti S,Taiberg L,Gurka D,Kumar A,Cheang M, Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Critical care medicine. 2006 Jun     [PubMed PMID: 16625125]

Level 2 (mid-level) evidence


Rivers E,Nguyen B,Havstad S,Ressler J,Muzzin A,Knoblich B,Peterson E,Tomlanovich M,Early Goal-Directed Therapy Collaborative Group., Early goal-directed therapy in the treatment of severe sepsis and septic shock. The New England journal of medicine. 2001 Nov 8     [PubMed PMID: 11794169]

Level 1 (high-level) evidence